Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss

Míreanna comhchosúla

• Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways
  de réir: El-Agamy DS, et al.
  Foilsithe / Cruthaithe: (2018-12-01)
• Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
  de réir: Guobin Qi, et al.
  Foilsithe / Cruthaithe: (2022-11-01)
• Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
  de réir: Hui Liu, et al.
  Foilsithe / Cruthaithe: (2021-03-01)
• Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways
  de réir: Dingwei Cang, et al.
  Foilsithe / Cruthaithe: (2021-08-01)
• Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis
  de réir: Ye Xiaoshuang, et al.
  Foilsithe / Cruthaithe: (2022-08-01)